GlassScriptPhysician profile
Jaime M Rawson
NPI 1508026469
$18,723.22
in general payments reported to CMS, 2019-2025
79 companies · $107 in 2025
The $107 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,466 · 2020: $2,773 · 2021: $3,207 · 2022: $4,007 · 2023: $4,088 · 2024: $2,075 · 2025: $107.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,205 · Education: $64.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,204.86 |
| Education | $64.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,963.22 | 2019-2025 | |
| Ucb, INC. | $1,659.64 | 2019-2024 | Briviact, Rystiggo, Zilbrysq |
| Novartis Pharmaceuticals Corporation | $1,208.86 | 2019-2024 | |
| Amgen INC. | $931.43 | 2019-2024 | Aimovig, Uplizna |
| Allergan, INC. | $843.16 | 2019-2021 | |
| Lilly USA, LLC | $838.97 | 2019-2025 | Emgality, Reyvow, Amyvid |
| Alexion Pharmaceuticals, INC. | $792.40 | 2019-2024 | Ultomiris |
| Teva Pharmaceuticals USA, INC. | $600.81 | 2019-2024 | Austedo Xr, Austedo, Ajovy |
| Genzyme Corporation | $555.94 | 2019-2023 | |
| Argenx US, INC. | $550.70 | 2022-2025 | Vyvgart Hytrulo, Vyvgart |
| Biogen, INC. | $475.23 | 2019-2023 | Vumerity, Spinraza |
| Genentech USA, INC. | $459.82 | 2019-2024 | Ocrevus, Enspryng |
| Csl Behring | $459.05 | 2020-2023 | Hizentra, Privigen |
| Upsher-Smith Laboratories LLC | $447.48 | 2019-2023 | |
| Amneal Pharmaceuticals LLC | $399.61 | 2019-2024 | Rytary, Lyvispah |
Show all 79 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jaime Rawson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.